ABBVIE INC. New York Stock Exchange
Open: $114.7 High: $116.19 Low: $113.61 Close: $114.61
Range: 2021-06-23 - 2021-06-24
Volume: 8,889,364
Market: Open
Powered by Finage Stock APIDelayed data
ABBVIE INC. 1 North Waukegan Road North Chicago IL, 60064-6400
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
  • CEO: Richard A. Gonzalez
  • Employees: 30,000
  • Sector: Healthcare
  • Industry: Drug Manufacturers
Latest news about the ABBV
  • AbbVie Is One Of The Biggest Pharma Companies, But Is It A Buy Right Now?

    Is AbbVie stock a buy now that shares are recovering somewhat after the Food and Drug Administration requested additional data before considering new approvals for Rinvoq?

    View More →
  • AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

    AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma (R/R MM). In February 2019, AbbVie and TeneoOne entered a strategic transaction to develop and commercialize TNB-383B, a bispecific antibody that simultaneously targets BCMA and CD3 and is designed to direct the body's own immune

    View More →
  • Invesco Canada announces cash distributions for its Canadian-listed ETFs

    Invesco Canada Ltd. ("Invesco") today announced the June 2021 distributions for its Canadian-listed exchange-traded funds (ETFs). Unitholders of record on June 29, 2021 will receive cash distributions payable on July 7, 2021.

    View More →
  • 2 Dividend Stocks That Could Be Paying You 10% Within 5 Years

    Income investors often shy away from high-yielding dividend stocks because of the risk. Dividend growth stocks pay more over time and can help you get to that level. Two top income stocks that you should consider today are AbbVie (NYSE: ABBV) and Enbridge (NYSE: ENB).

    View More →
  • AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

    AbbVie (ABBV) closed at $114.73 in the latest trading session, marking a +1.42% move from the prior day.

    View More →
  • UPDATE 1-U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug

    The U.S. Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel. The justices turned away AbbVie's appeal and left intact the lower court's finding that its 2011 complaint against Perrigo was brought solely to delay Perrigo's proposed generic version of AndroGel. The Philadelphia-based 3rd U.S. Circuit Court of Appeals last year threw out a federal judge's order requiring AbbVie and partner Besins Pharmaceuticals to disgorge $448 million in profits to the Federal Trade Commission, but found that the judge had correctly determined that they had violated antitrust law.

    View More →
  • This Is Warren Buffett's Best Dividend Stock by Far

    It might seem that Warren Buffett doesn't like dividends. After all, Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) has never paid a dividend. There are more stocks in Berkshire's portfolio that pay dividends than ones that don't.

    View More →
  • Warren Buffett's Highest-Yielding Dividend Stocks

    Warren Buffett, CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), is in a class of his own when it comes to investing. Since taking the helm at Berkshire Hathaway in the mid-1960s, he's delivered an average annual return of 20% for holders of its Class A shares. While there are a number of factors that have made Buffett an investing legend, perhaps the most overlooked reasons he's so successful are dividend stocks.

    View More →
  • Next Market Crash 101: 2 Top Growth Stocks to Buy Right Now

    Whether the volatility investors are currently seeing actually foreshadows another market crash is anyone's guess, and trying to time the market to predict the best windows for buying stocks can be a recipe for disaster. No matter how worried you may be about a crash, it's always a great time to invest in high-quality stocks that generate wealth-building portfolio returns. Facebook (NASDAQ: FB) is hardly a new choice for long-term investors, but it's the type of stock you can add more of to your portfolio time and time again.

    View More →
  • AbbVie Declares Quarterly Dividend

    The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share.

    View More →
  • Supreme Court upholds Obamacare in latest ruling

    On Thursday, the Supreme Court released its highly anticipated decision on a challenge to the Affordable Care Act (ACA), also known as Obamacare. By a 7-2 vote, the court rejected the Republican-led challenge to the law.

    View More →
  • 2 Top Dividend Stocks You Can Buy and Hold Forever

    Dividend stocks can be a great source of passive income, and fortunately, there is no shortage of dividend-paying companies in the stock market. After all, many companies slash, or outright suspend, their dividends once the economy stops working in their favor. If you are looking for dividend stocks that can pay you for the rest of your life, rest assured: They exist.

    View More →
  • Influencers with Andy Serwer: David Ricks

    In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

    View More →
  • Why AbbVie (ABBV) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

    View More →
  • 10 Best Dividend Stocks to Buy According to Billionaire Richard Chilton

    In this article, we discuss the 10 best dividend stocks to buy according to billionaire Richard Chilton. If you want to skip our detailed analysis of Chilton’s history and hedge fund performance, go directly to the 5 Best Dividend Stocks to Buy Now According to billionaire Richard Chilton. Note that all hedge fund data is […]

    View More →
  • FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO

    Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.

    View More →
  • Here is What Hedge Funds Think About AbbVie Inc (ABBV)

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

    View More →
  • AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, AbbVie (ABBV) closed at $115.40, marking a -0.02% move from the previous day.

    View More →
  • I-Mab Seeks Multibillion-Dollar Cancer Drug Partnership

    (Bloomberg) -- I-Mab is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as the Chinese firm aims to replicate the success of last year’s $2.9 billion deal with AbbVie Inc., according to people familiar with the matter.The Shanghai-based drug developer is working with advisers and is in talks with several global pharmaceutical companies over a potential deal for its Uliledlimab, or TJD5, treatment that could be worth a few billion dollars, the people said, asking not to

    View More →
  • JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients

    A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/Venclyxto (venetoclax) slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients. The phase 3 GLOW trial data were shared at the European Hematology Association (EHA) annual meeting. In the

    View More →